Pegaptanib Sodium (Macugen)

Pegaptanib (Macugen) is covered for neovascular (wet) age-related macular degeneration (FDA‑approved) and for diabetic macular edema (off‑label compendial use) but is excluded in the presence of ocular or periocular infection. Approval requires documentation of the diagnosis and that all coverage/safety criteria are met, limits dosing to 0.3 mg intravitreal every 6 weeks, and is authorized for up to 12 months.

"Neovascular (Wet) age-related macular degeneration (AMD) (FDA-approved indication)"

Sign up to see full coverage criteria, indications, and limitations.